Planet Labs PBC ( PL ) delivered a particularly strong 4Q26 beat, and the stock saw significant upside of about 25%. Revenue came in at $86.8 million, a figure that exceeded expectations by about $8.7 million, while the non-GAAP EPSI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an ...

AC Immune SA ( ACIU ) reported a FY25 GAAP EPS loss of CHF 0.70. Again, we saw continued losses typical of a clinical-stage biotech company. However, what was concerning was that revenue cameI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges ...

As you know, Viatris Inc. ( VTRS ) has just outlined a pretty ambitious long-term strategy through to 2030. The aim is to transform its base business into a much more durable, higher-marginI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges b ...

Lantern Pharma Conference Summary Company Overview - **Company**: Lantern Pharma (NasdaqCM: LTRN) - **Industry**: Biotechnology, specifically focused on oncology and AI-driven drug development Key Points and Arguments AI Utilization in Drug Development - Lantern Pharma is leveraging AI through its platform, RADR, to develop new cancer medicines, significantly reducing the time to bring drugs to clinical trials by 70%-80% [5][6] - The company has dosed over 100 patients in clinical trials with drugs developed using its AI platform [5] - AI is used to identify biomarkers that predict patient responses, increasing the likelihood of clinical trial success and reducing trial costs by 30%-50% [6][7] Clinical Trials and Drug Pipeline - Lantern has launched over 10 programs in the last two years, with several in phase one and phase two trials [7] - The company has received fast track designations for multiple drugs, including those targeting triple-negative breast cancer (TNBC) and brain cancers [10][11] - A new subsidiary, Starlight Therapeutics, has been created to focus on brain cancer treatments, with plans for future financing [11][26] Market Potential and Financials - The market opportunity for the drug LP-184 is estimated to exceed $10 billion [24] - Lantern has 12 FDA designations, including 2 fast track and 6 orphan designations, highlighting its strong regulatory position [18] - The company reported a capital of approximately $12 million with a burn rate of $4 million per quarter, providing sufficient runway into Q3 [27][28] AI Platform and Future Developments - The AI platform has processed approximately 500 billion data points, utilizing hundreds of algorithms for drug development [12] - Lantern is developing a subscription-based model for its AI platform, with the potential to monetize its capabilities for drug developers [15][29] - The company aims to position its AI platform as a leading tool in rare cancer research, with plans for further enhancements and public availability [15][37] Competitive Advantage - Lantern Pharma emphasizes its unique position in the market, claiming no other company of its size has achieved as many FDA designations or is conducting multiple trials simultaneously [39] - The RADR platform is publicly available under the name withZeta.ai, which has received positive feedback from early users, including major cancer institutions and pharmaceutical companies [40] Upcoming Milestones - Key catalysts for the upcoming year include data releases for LP-300 and LP-184, as well as the launch of Starlight Therapeutics [36] - The company anticipates significant developments in its AI platform, which could lead to further licensing opportunities with larger pharmaceutical companies [37] Additional Important Information - Lantern Pharma's approach combines drug development with AI capabilities, aiming to streamline processes and enhance the efficiency of clinical trials [20][21] - The company has established collaborations with various research institutions, enhancing its credibility and data access [16][17] - The focus on rare cancers and the development of innovative drugs positions Lantern Pharma as a potentially disruptive player in the biotechnology sector [16][26]

Intuitive Machines, Inc. ( LUNR ) reported Q4 '25 results, and it has to be said that the numbers on the surface appear quite weak. Revenue came in at $44.8 million, down 18% since last year and also missingI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigo ...

─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathway to Potential Approval for the Treatment of PSC─ ─Multiple Scientific Presentations and Publications Raised Awareness of Nebokitug’s Potential to Become the First Disease-Modifying Treatment for PSC and Its Relevance to Other Fibro-Inflammatory Conditions─ ─Discussions with Strategic Partners Continue to ...

Red Cat Holdings, Inc. ( RCAT ) has just reported somewhat mixed 4Q25 results; however, I still see the company on the right track. They posted a GAAP EPS of -$0.17, a figure that missed expectations byI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and ...

Group 1 - A Massachusetts federal judge has halted modifications to the U.S. childhood immunization schedule proposed by the HHS Secretary [1] - The article emphasizes the importance of combining scientific expertise with financial and market analysis in the biotech sector [1] - The focus is on identifying promising biotechnology companies that innovate through novel mechanisms of action and first-in-class therapies [1] Group 2 - The analysis aims to evaluate the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities [1] - The article highlights the potential for breakthrough science in biotech to lead to significant returns, while also noting the necessity for careful scrutiny [1]

Roche Bought Thousands Of Nvidia AI Chips To Speed Up Drug Development https://t.co/kaijj1zPqc (📸: Richard Morgenstein 2021) https://t.co/g8XjhUNcv5 ...

Group 1 - Structure Therapeutics (GPCR) released new topline data from the Phase 2 ACCESS II trial, resulting in a stock increase of approximately 5% [1] - The initial data from the trial is viewed positively, supporting a bullish outlook for the company [1] Group 2 - The focus is on identifying promising biotechnology companies that innovate through unique mechanisms of action, first-in-class therapies, or platform technologies [1] - The analysis emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]